Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the anti-CD20 antibody Rituximab, which demonstrated significant clinical response in three CFS patients. METHODS AND FINDINGS: In this double-blind, placebo-controlled phase II study (NCT00848692), 30 CFS patients were randomised to either Rituximab 500 mg/m(2) or saline, given twice two weeks apart, with follow-up for 12 months. Xenotropic murine leukemia virus-related virus (XMRV) was not detected in any of the patients. The responses generally affected all CFS symptoms. Major or moderate overall response, defined as lasting improvements in self-reported Fatigue score during follow-up, was seen in 10 out of 15 patients (67%) in the Rituximab group and in two out of 15 patients (13%) in the Placebo group (p = 0.003). Mean response duration within the follow-up period for the 10 responders to Rituximab was 25 weeks (range 8-44). Four Rituximab patients had clinical response durations past the study period. General linear models for repeated measures of Fatigue scores during follow-up showed a significant interaction between time and intervention group (p = 0.018 for self-reported, and p = 0.024 for physician-assessed), with differences between the Rituximab and Placebo groups between 6-10 months after intervention. The primary end-point, defined as effect on self-reported Fatigue score 3 months after intervention, was negative. There were no serious adverse events. Two patients in the Rituximab group with pre-existing psoriasis experienced moderate psoriasis worsening. CONCLUSION: The delayed responses starting from 2-7 months after Rituximab treatment, in spite of rapid B-cell depletion, suggests that CFS is an autoimmune disease and may be consistent with the gradual elimination of autoantibodies preceding clinical responses. The present findings will impact future research efforts in CFS. TRIAL REGISTRATION: ClinicalTrials.gov NCT00848692.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lombardi, V. C., Ruscetti, F. W., Das Gupta, J., Pfost, M. A., Hagen, K. S., Peterson, D. L., Ruscetti, S. K., Bagni, R. K., Petrow-Sadowski, C., Gold, B., et al. (2009) · Science · doi:10.1126/science.1179052 · Cited by 538 · cited 1×
“There has been an intense focus on XMRV as a possible causal gammaretroviral infection in CFS patients since the first report in October 2009 [25].”
BackgroundRetractedThe Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study
Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., Komaroff, A., & and International Chronic Fatigue Syndrome Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00009 · Cited by 4,969
Carruthers, B. M., Jain, A. K., De Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., Bested, A. C., Flor-Henry, P., Joshi, P., Powles, A. C. P., et al. (2003) · Journal of Chronic Fatigue Syndrome · doi:10.1300/j092v11n01_02 · Cited by 1,180 · cited 1×
“Retrospectively, we checked the 30 patients according to the Clinical Working Case Definition (‘‘Canadian criteria’’) [8].”
MethodPace, T. W. W., & Heim, C. M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.003 · Cited by 321 · cited 1×
“Although poorly understood, immune system alterations seen in stress-related diseases such as post-traumatic stress disorder could also be relevant for the effects of B-cell depletion seen in CFS [20].”
BackgroundNacul, L. C., Lacerda, E. M., Pheby, D., Campion, P., Molokhia, M., Fayyaz, S., Leite, J. C., Poland, F., Howe, A., & Drachler, M. L. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-91 · Cited by 255 · cited 1×
“2% of the population using strict diagnostic criteria [3].”
MethodRecombinant Origin of the Retrovirus XMRV
Paprotka, T., Delviks-Frankenberry, K. A., Cingöz, O., Martinez, A., Kung, H.-J., Tepper, C. G., Hu, W.-S., Fivash, M. J., Coffin, J. M., & Pathak, V. K. (2011) · Science · doi:10.1126/science.1205292 · Cited by 240
A formal analysis of cytokine networks in chronic fatigue syndrome
Broderick, G., Fuite, J., Kreitz, A., Vernon, S. D., Klimas, N., & Fletcher, M. A. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.04.012 · Cited by 202 · cited 1×
“A recent study of cytokine patterns in CFS showed attenuated Th1 and Th17 immune responses, while there was high Th2 marker expression [12].”
Background
Cited by
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Montoya, J. G., Holmes, T. H., Anderson, J. N., Maecker, H. T., Rosenberg-Hasson, Y., Valencia, I. J., Chu, L., Younger, J. W., Tato, C. M., & Davis, M. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710519114 · Cited by 402
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C., Arcos-Burgos, M., & Lidbury, B. (2019) · Diagnostics · doi:10.3390/diagnostics9030091 · Cited by 313
Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
the European Network on ME/CFS (EUROMENE), Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C., Murovska, M., & Prusty, B. K. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1644-y · Cited by 312
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease
Sotzny, F., Blanco, J., Capelli, E., Castro-Marrero, J., Steiner, S., Murovska, M., & Scheibenbogen, C. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.009 · Cited by 272
Distinct plasma immune signatures in ME/CFS are present early in the course of illness
Hornig, M., Montoya, J. G., Klimas, N. G., Levine, S., Felsenstein, D., Bateman, L., Peterson, D. L., Gottschalk, C. G., Schultz, A. F., Che, X., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400121 · Cited by 263
Brurberg, K. G., Fønhus, M. S., Larun, L., Flottorp, S., & Malterud, K. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-003973 · Cited by 259
Fluge, Ø., Mella, O., Bruland, O., Risa, K., Dyrstad, S. E., Alme, K., Rekeland, I. G., Sapkota, D., Røsland, G. V., Fosså, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89376 · Cited by 209
Self-citationRowe, P. C., Underhill, R. A., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M. S., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00121 · Cited by 204
“A small randomized trial in adults demonstrated improvement in ME/CFS symptoms after rituximab-mediated B-cell depletion (47), but there have been no pediatric studies.”
Smith, M. E. B., Haney, E., McDonagh, M., Pappas, M., Daeges, M., Wasson, N., Fu, R., & Nelson, H. D. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0114 · Cited by 142
“Additional trials enrolling fewer than 30 participants and with durations less than 12 weeks indicated no statistically significant differences compared with placebo for acyclovir (57) and showed improved 36-item ShortForm Survey (SF-36) scores for physical health and function with rituximab (58).”
BackgroundKhanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A., Newton, J. L., & Jones, D. E. (2019) · Hepatology · doi:10.1002/hep.30099 · Cited by 75
“Baseline biochemical parameters were typical of early-stage PBC. Median alkaline phosphatase values were 136 and 131 u/L in the rituximab and placebo groups, respectively.”
BackgroundInfluentialBradley, A. S., Ford, B., & Bansal, A. S. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12043 · Cited by 73
Nguyen, C. B., Alsøe, L., Lindvall, J. M., Sulheim, D., Fagermoen, E., Winger, A., Kaarbø, M., Nilsen, H., & Wyller, V. B. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1201-0 · Cited by 59
“Furthermore, the reported beneficial effect of treatment with the antiCD20 antibody rituximab might suggest a role for B cells in the pathophysiology [11].”
BackgroundFunctional bowel symptoms, fibromyalgia and fatigue: A food-induced triad?
Berstad, A., Undseth, R., Lind, R., & Valeur, J. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.690045 · Cited by 49
Mensah, F., Bansal, A., Berkovitz, S., Sharma, A., Reddy, V, Leandro, M. J., & Cambridge, G. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12749 · Cited by 34
Kim, D.-Y., Lee, J.-S., & Son, C.-G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113463 · Cited by 24
“Single item score (2) [33,53] Fatigue symptom (2) [20,62]”
BackgroundLunde, S., Kristoffersen, E. K., Sapkota, D., Risa, K., Dahl, O., Bruland, O., Mella, O., & Fluge, Ø. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161226 · Cited by 22
“The clinical data from the previous trials evaluating B-cell depletion for ME/CFS [11,12], indicates that a subgroup of ME/CFS patients has an immunological disease in which B-cells and possibly antibodies may be important for symptom maintenance.”
BackgroundMethodResultInfluentialKronisk utmattelsessyndrom/myalgisk encefalopati – sykdomsmekanismer, diagnostikk og behandling
Wyller, V. B., Reme, S. E., & Mollnes, T. E. (2015) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.15.1180 · Cited by 18
“In Norway, treatment with rituximab attracted attention after a small, placebo-controlled study (30 patients) suggested beneficial effects (43).”
BackgroundFritsch, P., Craddock, T. J., del Rosario, R. M., Rice, M. A., Smylie, A., Folcik, V. A., de Vries, G., Fletcher, M. A., Klimas, N. G., & Broderick, G. (2013) · Systems Biomedicine · doi:10.4161/sysb.28948 · Cited by 16
“This is consistent with evidence supporting an infectious etiology in at least some forms of CFS(86) and the relative success of recent trials involving depletion of the B cell population, a reservoir for EBV infection.(87) Even though care was taken to involve the principal regulatory interactions no model is complet…”
Result
Metadata
- Authors
- Fluge, Ø., Bruland, O., Risa, K., Storstein, A., Kristoffersen, E. K., Sapkota, D., Næss, H., Dahl, O., Nyland, H., & Mella, O.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-19
- Volume
- 6
- Issue
- 10
- Pages
- e26358
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2041818093
- Cited by
- 194
- References
- 7
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.